Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2012
11/07/2012EP2520570A1 Aminopyridine compound
11/07/2012EP2520294A2 Composition including naphthoquinone compound for treating and preventing hearing loss
11/07/2012EP2519238A1 Beta-carbolines for use in the treatment of hearing loss and vertigo
11/07/2012EP2519237A1 Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
11/07/2012EP2213737B1 Double-stranded oligonucleotides
11/07/2012CN1880301B Tiopronin lysine and its preparing process and use
11/07/2012CN102770141A Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
11/07/2012CN102770136A Therapeutic agent (Y - 39983) for corneal endothelial dysfunction
11/07/2012CN102770135A Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
11/07/2012CN102764261A Oral composition controlling release of trimetazidine dihydrochloride and preparation method of oral composition
11/07/2012CN102764231A Ophthalmic gel for treating herpes simplex viral keratitis and preparation method of ophthalmic gel
11/07/2012CN102114245B Special solvent for daidzein pre-emulsified injection and preparation method and purpose thereof
11/07/2012CN102106812B Azithromycin ultrafine powder in-situ gel eye drops and preparation method thereof
11/07/2012CN101837061B Pharmaceutical applications of Hawthorn leaves and extract thereof
11/06/2012US8304409 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
11/06/2012US8304405 Combination of azelastine and ciclesonide for nasal administration
11/06/2012US8303949 Prevention and treatment of oxidative stress disorders by glutathione and phase II detoxification enzymes
11/06/2012CA2365532C Arpe-19 as a platform cell line for encapsulated cell-based delivery
11/01/2012WO2012149452A1 Compounds, formulations, and methods of protein kinase c inhibition
11/01/2012WO2012148930A2 Oxidative retinal diseases
11/01/2012WO2012148547A1 Compositions and methods for treating inflammatory conditions of the ocular surface
11/01/2012WO2012121560A9 Composition for preventing or treating hearing loss
11/01/2012WO2012112543A3 Method and apparatus for the delivery of photo-chemical (cross-linking) treatment to scleral tissue
11/01/2012WO2012105854A3 Compositions for administration to the eye
11/01/2012WO2012102625A3 Therapeutic composition
11/01/2012WO2012092510A3 Ocular drug delivery system
11/01/2012WO2012088044A3 Compositions and methods for improving ocular surface health, corneal clarity, optical function and maintaining visual acuity
11/01/2012US20120277305 Fatty acid guanidine and salicylate guanidine derivatives and their uses
11/01/2012US20120277288 Means and Methods for the Specific Modulation of Target Genes in the CNS and the Eye and Methods for Their Identification
11/01/2012US20120277277 Methods of Treating a Hyperproliferative Disorder or Inhibiting Cell Growth in a Mammal
11/01/2012US20120277259 Substituted benzofused derivatives and their use as vanilloid receptor ligands
11/01/2012US20120277240 Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes
11/01/2012US20120277239 Compositions and Methods for Improving Night Vision
11/01/2012US20120277228 Novel Azaheterocyclic Compounds
11/01/2012US20120277199 Modulation of Gel Temperature of Poloxamer-Containing Formulations
11/01/2012US20120277191 Forms of cidofovir
11/01/2012US20120277173 Stabilized anthocyanin compositions
11/01/2012US20120277144 Novel compounds for modulating neovascularisation and methods of treatment using these compounds
11/01/2012US20120277142 Modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof, and method for preparing same
11/01/2012US20120276215 Therapeutic Conditioned Media
11/01/2012US20120276192 Compositions and methods for sirna inhibition of icam-1
11/01/2012US20120276186 Sustained release latanoprost implant
11/01/2012US20120276184 Solvent cast film sustained release latanoprost implant
11/01/2012US20120276127 Treatment of retinal disorders with recombinant t cell receptor ligand (rtl)
11/01/2012US20120276117 Binding Partners for the Thyrotropin Receptor and Uses Thereof
11/01/2012US20120276111 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
11/01/2012US20120276106 Klk-13 antibody inhibitor for treating dry eye
11/01/2012US20120276090 Gene recombinant antibody and antibody fragment thereof
11/01/2012US20120276084 Predicting Risk of Age-Related Macular Degeneration
11/01/2012US20120276083 Methods for inhibiting ocular angiogenesis
11/01/2012US20120276049 Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
11/01/2012CA2834676A1 Methods of predicting the development of complement-mediated disease
11/01/2012CA2834341A1 Oxidative retinal diseases
11/01/2012CA2833806A1 Method for treatment of macular degeneration by modulating p2y12 or p2x7 receptors
10/2012
10/31/2012EP2518056A1 Seven-membered ring compound and pharmaceutical use therefor
10/31/2012EP2517728A1 Drug for preventing or treating angiogenic eye diseases
10/31/2012EP2517711A1 Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages
10/31/2012EP2516393A1 Carboxamide compounds and their use as calpain inhibitors
10/31/2012EP2515926A1 Compositions and methods for the treatment of angiogenesis-related eye diseases
10/31/2012EP2515917A1 Compositions and methods for eye whitening
10/31/2012EP2515864A1 Sustained release delivery devices
10/31/2012EP2515655A1 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
10/31/2012CN102762195A Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
10/31/2012CN102757461A Modified lecithin complexed iodine, and preparation method and application thereof
10/31/2012CN102757448A Macrocyclic kinase inhibitor compound, preparation method and application thereof as drug
10/31/2012CN102757441A Furano[3,2-g]chromene compounds and applications thereof
10/31/2012CN102755646A Medicament for treating TNF alpha related disorder
10/31/2012CN102755606A Traditional Chinese medicine preparation for treating retinal vein obstruction due to stagnation of liver Qi
10/31/2012CN102755561A Health care product used for diabetic fundus hemorrhage
10/31/2012CN102755549A Drug for curing cataract and preparation method thereof
10/31/2012CN102755468A External use health care product for reducing intraocular pressure of diabetes mellitus eye diseases
10/31/2012CN102755466A Ear drops medicine for treating acute suppurative otitis media
10/31/2012CN102755438A Chinese medicine for treating nearsightedness
10/31/2012CN102755430A Traditional Chinese medicine composition for treating conjunctivitis by external use and applications of composition
10/31/2012CN101959514B Prophylactic or therapeutic agent for ocular disease accompanied by optic nerve disorder
10/31/2012CN101874811B Preparation method of silica modified nano pearl powder
10/31/2012CN101679317B Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor binding activity
10/31/2012CN101293038B Gallbladder leaves extract, preparing method, its preparation and uses
10/31/2012CN101278936B Clear eye lotion containing latanoprost as effective ingredient
10/31/2012CN101244076B Pharmaceutical combination of azithromycin for eyes
10/30/2012US8299064 Fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
10/30/2012US8299030 Peptide-based compounds
10/30/2012US8298521 Treatment for eye disorder
10/30/2012CA2448302C Lipoxin compounds
10/26/2012WO2012144661A1 Aromatic heterocyclic derivative having trpv4-inhibiting activity
10/26/2012WO2012144478A1 Tetrahydrothiazepine derivative
10/26/2012WO2012143143A1 Heterocyclic compounds as kinase inhibitors
10/26/2012WO2012099940A3 Methods and compositions for treating ocular disease
10/26/2012CA2833785A1 Compositions and methods for the treatment of neuromyelitis optica
10/26/2012CA2831680A1 Heterocyclic compounds as kinase inhibitors
10/25/2012US20120270955 Ophthalmic composition with a viscosity enhancement system having two different viscosity enhancing agents
10/25/2012US20120270954 Methods for maintaining eye health and ameliorating opthalmic maladies in canines
10/25/2012US20120270953 Methods and compositions for the treatment of infection or infectious colonization of the eyelid, ocular surface, skin or ear
10/25/2012US20120270946 Crystalline form of bimatoprost, preparation method and use thereof
10/25/2012US20120270922 Antiangiogenic Agent and Method for Inhibition of Angiogenesis
10/25/2012US20120270912 Substituted Indolealkanoic Acids
10/25/2012US20120270910 Pharmaceutical containing ppar-delta agonist
10/25/2012US20120270907 Therapeutic uses of nicotine
10/25/2012US20120270898 Sulfonamide compound and crystal thereof
10/25/2012US20120270889 Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
1 ... 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 ... 531